• 1
    Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009; 26: 1934.
  • 2
    Chaudary N, Hill RP. Hypoxia and metastasis in breast cancer. Breast Dis 2006; 26: 5564.
  • 3
    Milosevic M, Chung P, Parker C et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 2007; 67: 60225.
  • 4
    Milosevic M, Warde P, Menard C et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012; 18: 210814.
  • 5
    Benham AM, Cabibbo A, Fassio A, Bulleid N, Sitia R, Braakman I. The CXXCXXC motif determines the folding, structure and stability of human ERO1-Lalpha. EMBO J 2000; 19: 4493502.
  • 6
    Gess B, Hofbauer KH, Wenger RH, Lohaus C, Meyer HE, Kurtz A. The cellular oxygen tension regulates expression of the endoplasmic oxidoreductase ERO1-Lalpha. Eur J Biochem 2003; 270: 222835.
  • 7
    Araki K, Nagata K. Functional in vitro analysis of the ERO1 protein and protein-disulfide isomerase pathway. J Biol Chem 2011; 286: 3270512.
  • 8
    Masui S, Vavassori S, Fagioli C, Sitia R, Inaba K. Molecular bases of cyclic and specific disulfide interchange between human ERO1alpha and PDI. J Biol Chem 2011; 286: 1626171.
  • 9
    Tavender TJ, Bulleid NJ. Molecular mechanisms regulating oxidative activity of the ERO1 family in the endoplasmic reticulum. Antioxid Redox Signal 2010; 13: 117787.
  • 10
    Tanaka S, Uehara T, Nomura Y. Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death. J Biol Chem 2000; 275: 1038893.
  • 11
    May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E. ERO1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer. Oncogene 2005; 24: 101120.
  • 12
    Qin C, Wilson C, Blancher C, Taylor M, Safe S, Harris AL. Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis. Clin Cancer Res 2001; 7: 81823.
  • 13
    Schindl M, Schoppmann SF, Samonigg H et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002; 8: 18317.
  • 14
    Potgens AJ, Lubsen NH, van Altena MC et al. Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J Biol Chem 1994; 269: 3287985.
  • 15
    Claffey KP, Senger DR, Spiegelman BM. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim Biophys Acta 1995; 1246: 19.
  • 16
    Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A 1997; 94: 71927.
  • 17
    Frand AR, Kaiser CA. ERO1p oxidizes protein disulfide isomerase in a pathway for disulfide bond formation in the endoplasmic reticulum. Mol Cell 1999; 4: 46977.